Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
58
KNSA Quote, Financials, Valuation and Earnings
Last price:
$41.08
Seasonality move
:
7.4%
Day range:
$39.79 - $41.48
52-week range:
$17.82 - $42.98
Dividend yield:
0%
P/E ratio:
90.54x
P/S ratio:
5.20x
P/B ratio:
5.75x
Volume:
231.8K
Avg. volume:
440.1K
1-year change:
93.99%
Market cap:
$3.1B
Revenue:
$423.2M
EPS (TTM):
$0.45
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$167.4M | $0.37 | 60.47% | -62.86% | $54.00 |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$277.2M | $0.15 | 12.73% | -82.4% | $29.05 |
|
ADMA
ADMA Biologics, Inc.
|
$130.5M | $0.16 | 18.96% | -57.14% | $27.25 |
|
AKAN
Akanda Corp.
|
-- | -- | -- | -- | -- |
|
CRMD
CorMedix, Inc.
|
$86M | $0.63 | 308.6% | 219.78% | $19.00 |
|
PHAR
Pharming Group NV
|
$91.2M | $0.00 | 10.75% | -67.59% | $31.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$40.59 | $54.00 | $3.1B | 90.54x | $0.00 | 0% | 5.20x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$26.55 | $29.05 | $4.5B | 17.08x | $0.00 | 0% | 4.27x |
|
ADMA
ADMA Biologics, Inc.
|
$20.11 | $27.25 | $4.8B | 23.62x | $0.00 | 0% | 10.12x |
|
AKAN
Akanda Corp.
|
$0.95 | -- | $689K | -- | $0.00 | 0% | 1.77x |
|
CRMD
CorMedix, Inc.
|
$10.64 | $19.00 | $838.3M | 5.18x | $0.00 | 0% | 3.58x |
|
PHAR
Pharming Group NV
|
$15.81 | $31.00 | $1.1B | 1,105.59x | $0.00 | 0% | 2.98x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
1.78% | -0.243 | 0.33% | 3.27x |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
5.64% | 2.330 | 1.52% | 2.70x |
|
ADMA
ADMA Biologics, Inc.
|
16.16% | -2.565 | 2.38% | 3.53x |
|
AKAN
Akanda Corp.
|
7.2% | 1.308 | 5.92% | 1.17x |
|
CRMD
CorMedix, Inc.
|
1.16% | 3.481 | 0.48% | 1.60x |
|
PHAR
Pharming Group NV
|
33.1% | -0.371 | 13.18% | 2.39x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
KNSA
Kiniksa Pharmaceuticals International Plc
|
$97.3M | $24M | 7.44% | 7.6% | 13.28% | $33M |
|
ACAD
ACADIA Pharmaceuticals, Inc.
|
$257M | $35.8M | 31.98% | 34.23% | 12.83% | $73.9M |
|
ADMA
ADMA Biologics, Inc.
|
$75.6M | $51M | 47.04% | 58.71% | 38.01% | -$1.1M |
|
AKAN
Akanda Corp.
|
-- | -- | -276.52% | -389.63% | -- | -- |
|
CRMD
CorMedix, Inc.
|
$93.1M | $51.3M | 94.54% | 95.25% | 49.24% | $30.4M |
|
PHAR
Pharming Group NV
|
$89.8M | $15.8M | 0.25% | 0.39% | 16.34% | $29.9M |
Kiniksa Pharmaceuticals International Plc vs. Competitors
-
Which has Higher Returns KNSA or ACAD?
ACADIA Pharmaceuticals, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 25.76%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat ACADIA Pharmaceuticals, Inc.'s return on equity of 34.23%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M ACADACADIA Pharmaceuticals, Inc.92.23% $0.42 $972.1M -
What do Analysts Say About KNSA or ACAD?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.00, signalling upside risk potential of 33.04%. On the other hand ACADIA Pharmaceuticals, Inc. has an analysts' consensus of $29.05 which suggests that it could grow by 9.43%. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than ACADIA Pharmaceuticals, Inc., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than ACADIA Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 ACADACADIA Pharmaceuticals, Inc.9 6 1 -
Is KNSA or ACAD More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison ACADIA Pharmaceuticals, Inc. has a beta of 0.670, suggesting its less volatile than the S&P 500 by 32.982%.
-
Which is a Better Dividend Stock KNSA or ACAD?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ACADIA Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. ACADIA Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or ACAD?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are smaller than ACADIA Pharmaceuticals, Inc. quarterly revenues of $278.6M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than ACADIA Pharmaceuticals, Inc.'s net income of $71.8M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 90.54x while ACADIA Pharmaceuticals, Inc.'s PE ratio is 17.08x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.20x versus 4.27x for ACADIA Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.20x 90.54x $180.9M $18.4M ACADACADIA Pharmaceuticals, Inc.4.27x 17.08x $278.6M $71.8M
-
Which has Higher Returns KNSA or ADMA?
ADMA Biologics, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 27.14%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat ADMA Biologics, Inc.'s return on equity of 58.71%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M ADMAADMA Biologics, Inc.56.32% $0.15 $514.3M -
What do Analysts Say About KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.00, signalling upside risk potential of 33.04%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $27.25 which suggests that it could grow by 35.51%. Given that ADMA Biologics, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe ADMA Biologics, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 ADMAADMA Biologics, Inc.4 0 0 -
Is KNSA or ADMA More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.433, suggesting its less volatile than the S&P 500 by 56.749%.
-
Which is a Better Dividend Stock KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or ADMA?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than ADMA Biologics, Inc. quarterly revenues of $134.2M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than ADMA Biologics, Inc.'s net income of $36.4M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 90.54x while ADMA Biologics, Inc.'s PE ratio is 23.62x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.20x versus 10.12x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.20x 90.54x $180.9M $18.4M ADMAADMA Biologics, Inc.10.12x 23.62x $134.2M $36.4M
-
Which has Higher Returns KNSA or AKAN?
Akanda Corp. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of --. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat Akanda Corp.'s return on equity of -389.63%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M AKANAkanda Corp.-- -- $4.9M -
What do Analysts Say About KNSA or AKAN?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.00, signalling upside risk potential of 33.04%. On the other hand Akanda Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Kiniksa Pharmaceuticals International Plc has higher upside potential than Akanda Corp., analysts believe Kiniksa Pharmaceuticals International Plc is more attractive than Akanda Corp..
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 AKANAkanda Corp.0 0 0 -
Is KNSA or AKAN More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison Akanda Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KNSA or AKAN?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Akanda Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. Akanda Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or AKAN?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than Akanda Corp. quarterly revenues of --. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than Akanda Corp.'s net income of --. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 90.54x while Akanda Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.20x versus 1.77x for Akanda Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.20x 90.54x $180.9M $18.4M AKANAkanda Corp.1.77x -- -- --
-
Which has Higher Returns KNSA or CRMD?
CorMedix, Inc. has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 49.9%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat CorMedix, Inc.'s return on equity of 95.25%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M CRMDCorMedix, Inc.89.26% $1.26 $378.5M -
What do Analysts Say About KNSA or CRMD?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.00, signalling upside risk potential of 33.04%. On the other hand CorMedix, Inc. has an analysts' consensus of $19.00 which suggests that it could grow by 78.57%. Given that CorMedix, Inc. has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe CorMedix, Inc. is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 CRMDCorMedix, Inc.4 0 0 -
Is KNSA or CRMD More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison CorMedix, Inc. has a beta of 1.322, suggesting its more volatile than the S&P 500 by 32.155%.
-
Which is a Better Dividend Stock KNSA or CRMD?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CorMedix, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. CorMedix, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or CRMD?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than CorMedix, Inc. quarterly revenues of $104.3M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is lower than CorMedix, Inc.'s net income of $108.6M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 90.54x while CorMedix, Inc.'s PE ratio is 5.18x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.20x versus 3.58x for CorMedix, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.20x 90.54x $180.9M $18.4M CRMDCorMedix, Inc.3.58x 5.18x $104.3M $108.6M
-
Which has Higher Returns KNSA or PHAR?
Pharming Group NV has a net margin of 10.19% compared to Kiniksa Pharmaceuticals International Plc's net margin of 7.71%. Kiniksa Pharmaceuticals International Plc's return on equity of 7.6% beat Pharming Group NV's return on equity of 0.39%.
Company Gross Margin Earnings Per Share Invested Capital KNSAKiniksa Pharmaceuticals International Plc53.78% $0.23 $545.1M PHARPharming Group NV92.7% $0.11 $395.6M -
What do Analysts Say About KNSA or PHAR?
Kiniksa Pharmaceuticals International Plc has a consensus price target of $54.00, signalling upside risk potential of 33.04%. On the other hand Pharming Group NV has an analysts' consensus of $31.00 which suggests that it could grow by 96.08%. Given that Pharming Group NV has higher upside potential than Kiniksa Pharmaceuticals International Plc, analysts believe Pharming Group NV is more attractive than Kiniksa Pharmaceuticals International Plc.
Company Buy Ratings Hold Ratings Sell Ratings KNSAKiniksa Pharmaceuticals International Plc6 0 0 PHARPharming Group NV2 0 0 -
Is KNSA or PHAR More Risky?
Kiniksa Pharmaceuticals International Plc has a beta of 0.017, which suggesting that the stock is 98.312% less volatile than S&P 500. In comparison Pharming Group NV has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock KNSA or PHAR?
Kiniksa Pharmaceuticals International Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pharming Group NV offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kiniksa Pharmaceuticals International Plc pays -- of its earnings as a dividend. Pharming Group NV pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios KNSA or PHAR?
Kiniksa Pharmaceuticals International Plc quarterly revenues are $180.9M, which are larger than Pharming Group NV quarterly revenues of $96.9M. Kiniksa Pharmaceuticals International Plc's net income of $18.4M is higher than Pharming Group NV's net income of $7.5M. Notably, Kiniksa Pharmaceuticals International Plc's price-to-earnings ratio is 90.54x while Pharming Group NV's PE ratio is 1,105.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kiniksa Pharmaceuticals International Plc is 5.20x versus 2.98x for Pharming Group NV. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income KNSAKiniksa Pharmaceuticals International Plc5.20x 90.54x $180.9M $18.4M PHARPharming Group NV2.98x 1,105.59x $96.9M $7.5M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 61x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
67
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Sell
39
PSTG alert for Dec 5
Pure Storage, Inc. [PSTG] is up 5.05% over the past day.
Sell
38
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
69
ASTS alert for Dec 5
AST Spacemobile, Inc. [ASTS] is up 18.25% over the past day.
